The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Grossman Adam S since 2015.
This trader's CIK number is 1542517.
At the time of last reporting, Grossman Adam S was the President and CEO of Adma Biologics, Inc.. (stock ticker symbol ADMA).
Also see all insider trading activities at Adma Biologics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | ADMA | 0 | $0 | 147,000 | $2,831,640 | 105,000 | $567,000 |
| 2024 | ADMA | 0 | $0 | 775,212 | $13,028,986 | 626,245 | $2,853,438 |
| 2023 | ADMA | 0 | $0 | 760,472 | $3,357,322 | 2,100,459 | $6,135,440 |
| 2021 | ADMA | 350,000 | $350,000 | 0 | $0 | 0 | $0 |
| 2020 | ADMA | 95,714 | $327,214 | 0 | $0 | 0 | $0 |
| 2019 | ADMA | 30,000 | $120,000 | 0 | $0 | 0 | $0 |
| 2018 | ADMA | 73,222 | $350,001 | 0 | $0 | 0 | $0 |
| 2017 | ADMA | 485,000 | $1,042,750 | 0 | $0 | 42,021 | $112,616 |
| 2016 | ADMA | 200,000 | $1,300,000 | 0 | $0 | 0 | $0 |
| 2015 | ADMA | 33,211 | $281,346 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-08-15 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-08-15 | ADMA | Sale | 21,000 | 16.88 | 354,480 |
| 2025-07-15 | ADMA | Sale | 21,000 | 18.66 | 391,860 |
| 2025-07-15 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-07-15 | ADMA | Sale | 21,000 | 18.66 | 391,860 |
| 2025-07-15 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-06-16 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-06-16 | ADMA | Sale | 21,000 | 20.81 | 437,010 |
| 2025-05-15 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-05-15 | ADMA | Sale | 21,000 | 19.45 | 408,450 |
| 2025-04-15 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-04-15 | ADMA | Sale | 21,000 | 21.46 | 450,660 |
| 2025-03-19 | ADMA | Option Ex | 15,000 | 5.40 | 81,000 |
| 2025-03-19 | ADMA | Sale | 21,000 | 18.92 | 397,320 |
| 2024-11-22 | ADMA | Sale | 48,967 | 21.10 | 1,033,203 |
| 2024-08-27 | ADMA | Sale | 389,356 | 17.29 | 6,732,743 |
| 2024-08-26 | ADMA | Sale | 236,889 | 17.69 | 4,191,040 |
| 2024-08-27 | ADMA | Option Ex | 389,356 | 3.13 | 1,219,852 |
| 2024-08-26 | ADMA | Option Ex | 236,889 | 6.90 | 1,633,586 |
| 2024-06-14 | ADMA | Sale | 100,000 | 10.72 | 1,072,000 |
| 2023-08-18 | ADMA | Sale | 250,000 | 4.15 | 1,038,249 |
| 2023-08-15 | ADMA | Option Ex | 2,100,459 | 2.92 | 6,135,440 |
| 2023-08-15 | ADMA | Sale | 510,469 | 4.54 | 2,319,060 |
| 2023-08-16 | ADMA | Sale | 3 | 4.38 | 13 |
| 2021-10-25 | ADMA | Buy | 350,000 | 1.00 | 350,000 |
| 2020-09-08 | ADMA | Buy | 4,000 | 2.24 | 8,960 |
| 2020-08-10 | ADMA | Buy | 5,000 | 3.06 | 15,285 |
| 2020-08-11 | ADMA | Buy | 1,000 | 2.97 | 2,970 |
| 2020-02-11 | ADMA | Buy | 85,714 | 3.50 | 299,999 |
| 2019-05-17 | ADMA | Buy | 30,000 | 4.00 | 120,000 |
| 2018-06-08 | ADMA | Buy | 73,222 | 4.78 | 350,001 |
| 2017-11-09 | ADMA | Buy | 485,000 | 2.15 | 1,042,750 |
| 2017-07-13 | ADMA | Option Ex | 42,021 | 2.68 | 112,616 |
| 2016-05-03 | ADMA | Buy | 200,000 | 6.50 | 1,300,000 |
| 2015-12-18 | ADMA | Buy | 6,400 | 8.47 | 54,227 |
| 2015-12-07 | ADMA | Buy | 200 | 9.02 | 1,803 |
| 2015-12-08 | ADMA | Buy | 300 | 8.99 | 2,697 |
| 2015-12-02 | ADMA | Buy | 2,250 | 9.15 | 20,589 |
| 2015-12-01 | ADMA | Buy | 1,800 | 9.17 | 16,513 |
| 2015-11-25 | ADMA | Buy | 1,800 | 9.18 | 16,529 |
| 2015-11-20 | ADMA | Buy | 2,861 | 9.19 | 26,289 |
| 2015-11-19 | ADMA | Buy | 1,000 | 9.13 | 9,134 |
| 2015-03-19 | ADMA | Buy | 2,000 | 8.50 | 16,996 |
| 2015-03-16 | ADMA | Buy | 9,100 | 7.99 | 72,690 |
| 2015-03-17 | ADMA | Buy | 5,500 | 7.98 | 43,879 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Grossman Adam S (President and CEO of Adma Biologics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.